QUINAPLUS

This brand name is authorized in Estonia, Germany.

Active ingredients

The drug QUINAPLUS contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Quinapril UNII `33067B3N2M` - QUINAPRIL HYDROCHLORIDE
	Quinapril is a potent angiotensin-converting enzyme (ACE) inhibitor. The mode of action of quinapril in humans and animals is to inhibit circulating and tissue ACE activity, thereby decreasing vasopressor activity and aldosterone secretion.
	Read more about Quinapril
`2`	Hydrochlorothiazide UNII `0J48LPH2TH` - HYDROCHLOROTHIAZIDE
	Hydrochlorothiazide is a diuretic with antihypertensive properties. It acts by inhibiting the renal tubular re-absorption of sodium and chloride ions, which are excreted with an accompanying volume of water. Potassium excretion is also promoted.
	Read more about Hydrochlorothiazide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09BA06	Quinapril and diuretics	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BA ACE inhibitors and diuretics
Discover more medicines within C09BA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00710575, 00715035, 00790108, 00840496, 00840510, 00840533, 00840556, 00840591
EE	Ravimiamet	1885024, 1885967

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.